Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some major efficacy/dosing elements and multiple safety concepts (hallucinations, dizziness, withdrawal/confusion, renal adjustments, NMDA antagonism) align with the provided label text, but several extracted safety/toxicity claims are unsupported or appear to rely on incorrect/miscited label sections, and important label areas (notably contraindications/boxed warnings) are not evaluated from the provided response.
Category Scores
Accurate Statements
Gocovri is the brand name for an extended-release form of amantadine (amantadine hydrochloride).
Supported by 11 DESCRIPTION.
Gocovri is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy (with or without concomitant dopaminergic medications).
Supported by 1 INDICATIONS AND USAGE.
Gocovri is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing 'off' episodes.
Supported by 1 INDICATIONS AND USAGE.
Gocovri is administered orally once daily at bedtime; initial 137 mg once daily at bedtime then increase after one week to 274 mg once daily at bedtime.
Supported by 2.1 Dosing Information.
Gocovri is not substitutable with other amantadine immediate- or extended-release products.
Supported by 2.1 Dosing Information.
Amantadine is a weak uncompetitive antagonist of the NMDA receptor.
Supported by 12.1 Mechanism of Action.
Possible side effects include dizziness; the label reports dizziness and orthostatic hypotension-related events.
Supported by 5.4 Dizziness and Orthostatic Hypotension.
Possible side effects include confusion.
Supported by 5.5 Withdrawal-Emergent Hyperpyrexia and Confusion.
Possible side effects include hallucinations.
Supported by 5.3 Hallucinations/Psychotic Behavior and 5.5.
Hallucinations may occur more frequently in older adults.
Supported by 8.5 Geriatric Use and 5.3.
Dosing should be adjusted in renal impairment; dose adjustment ranges are provided by creatinine clearance categories.
Supported by 2.3 Dosing in Patients with Renal Impairment.
Avoid sudden discontinuation; abrupt discontinuation may cause worsening Parkinson's symptoms or delirium and other neuropsychiatric effects; avoid sudden discontinuation.
Supported by 5.5 Withdrawal-Emergent Hyperpyrexia and Confusion and 2.4 Discontinuation.
Drug interaction potential exists (e.g., alcohol not recommended; anticholinergic potentiation; urine pH affecting excretion).
Supported by 5.4 (alcohol not recommended) and 7.1/7.2 Drug Interactions.
Gocovri should not be used with other amantadine products.
Supported by 2.1 Dosing Information (not substitutable with other amantadine immediate- or extended-release products).
Unsupported Statements
Possible side effects of Gocovri include dry mouth.
The response’s provided label mapping cites 12.1 as the adverse-reaction basis, which is not the adverse-reactions listing location in the provided label excerpts; the statement is plausible but is not supported as an adverse-reaction claim using the supplied label sections/citations.
Possible side effects of Gocovri include constipation.
The response’s provided label mapping cites 12.1 as the adverse-reaction basis; the statement is not supported as an adverse-reaction claim by the provided adverse-reaction sections/citations.
Possible side effects of Gocovri include nausea.
Marked as absent from the label in the claim evaluation, and no confirming label excerpt/citation for nausea is provided in the supplied label sections; cannot verify from provided label excerpts.
Gocovri is used to help modulate dopamine-related movement problems.
No matching support in the provided label excerpts; the label lists indications for dyskinesia and 'off' episodes but does not use this exact phrasing.
Gocovri is not a cure for Parkinson’s.
No matching support in the provided label excerpts for the claim that it is not a cure.
Gocovri can rarely cause skin changes like livedo reticularis.
No matching support in the provided label excerpts.
Contradictions
Important Omissions
Contraindications and boxed warning status were not evaluated in the provided compliance assessment.
Importance:
High
The AI’s extracted claims do not mention the second FDA-approved indication ('off' episodes) and thus only partially cover labeled indications.
Importance:
Moderate
No label-based description was provided for monitoring requirements beyond dizziness/orthostatic hypotension and hallucinations observation; other monitoring referenced in the full label (e.g., for somnolence/falls, suicidality/depression) is not captured in extracted claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several adverse-effect statements are unsupported or appear miscited/incorrectly anchored to non-adverse-reaction sections (dry mouth/constipation; nausea unverified), and contraindications/boxed warnings are not assessed, which could affect safe use accuracy.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Adverse reaction claims (dry mouth/constipation/nausea) show label-citation/mapping issues, and some statements are unsupported; additionally, contraindications/boxed warnings are not evaluated and one labeled indication ('off' episodes) is omitted from the extracted claims.
Suggested Improvement
Remove or re-verify unsupported adverse reactions and any claims not supported by the provided label excerpts; explicitly cover both FDA-approved indications from 1 INDICATIONS AND USAGE; ensure adverse-reaction claims cite appropriate adverse-reaction/Warnings sections from the label; include contraindications/boxed warning evaluation when assessing safety alignment.